###### Strengths and limitations of this study

-   Identified key domains that are used to define acute events by undertaking a comprehensive synthesis of definitions used in the medical literature.

-   Broad search strategy covering a wide range of databases including bibliography checks and conference abstracts.

-   Prospectively registered with an international register of systematic reviews (PROSPERO).
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-   Did not include potential synonyms as search terms ('attack', 'episode', 'fluctuations').

-   Data extraction was performed by only a single reviewer.

Introduction {#s1}
============

Recurrent acute events or episodes feature in the natural history of many chronic health conditions. The extent to which they characterise the condition varies, as do the presumed pathophysiological mechanisms, and scientific and lay terms used to describe them (eg, an acute exacerbation of chronic obstructive pulmonary disease (COPD) or asthma, an attack of gout or a rheumatoid arthritis flare). With recognition of their importance has come concerted effort to define these phenomena. Definitions for exacerbations or flares currently exist for COPD,[@R1] asthma,[@R3] systemic lupus erythematosus (SLE)[@R4] and ankylosing spondylitis (AS)[@R5] and there are working groups currently trying to define these for rheumatoid arthritis,[@R6] gout[@R9] and atopic dermatitis/eczema.[@R10] Despite the different language used, these definitions share some common, core domains: the onset or worsening of symptoms and signs above normal day-to-day variability; speed of onset; duration of sustained worsening and change in medication/healthcare usage.

Osteoarthritis (OA) appears to comprise multiple disease trajectories[@R11] and symptom variability over time and the presence of intermittent pain is well-recognised.[@R16] Although OA does not typically have the same very obvious acute events as conditions like gout, flares in OA joints are encountered in practice, these phenomena appear in patient literature,[@R17] have been discussed in expert reviews[@R18] and are mentioned in 'flare design' trials in OA.[@R19] These studies induce acute episodes of pain or flare-ups by asking patients to withdraw their usual medication.

In 2009, Marty *et al* proposed scoring criteria for knee OA flares based on nocturnal awakening, knee effusion, morning stiffness and limping,[@R20] but it is unclear whether this has contributed to a common understanding, shared terminology and criteria. A common definition of OA flare could be important for a number of reasons: (i) to facilitate communication between researchers, (ii) to allow more direct comparisons between studies on frequencies, determinants and course of events, (iii) to facilitate new insights into novel pathophysiological mechanisms and treatments through valid and homogenous case definitions and (iv) to help clinicians with prompt diagnosis and management.

The aim of this systematic review was to explore the extent to which a concept of OA flare is reported in the medical literature and the prospects for a common, shared definition of these for research and clinical application.

Methods {#s2}
=======

This systematic review was registered with PROSPERO registration number CRD42014010169. The review protocol has not been published.

Literature sources and study selection {#s2a}
--------------------------------------

We searched electronic databases from inception to July 2017; ASSIA, EMBASE, Web of Science, Health Management Information Consortium (HMIC), SPORTDiscus, Medline, CINAHL, PsycINFO, AMED, Ageline, Cochrane Database of Systematic Reviews and Cochrane Controlled Clinical Trials (CENTRAL). The search was developed using previously piloted terms for knee OA and a literature search for common terms used to describe acute events. Searches used combined and/or truncated key terms including: ('KNEE OSTEOARTHRITIS' OR (knee N3 pain) OR (knee N3 arthrosis) OR (knee N3 joint) OR (knee N3 osteoarthritis)) AND (exacerbation OR flare OR (pain AND (diary OR diaries)) OR (pain N3 variab\*) OR (pain N3 \*) OR (pain N3 \*) OR (pain N3 \*) OR (pain N3 pattern\$) OR (daily N3 pain)). A database search strategy is included in the online [supplementary table 1](#SP1){ref-type="supplementary-material"}. Reference lists of all included full-text articles retrieved for detailed examination were manually searched.
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Studies were included in the final full-text peer-review if they contained a description or definition of an acute exacerbation or flare-up of knee OA in human adults (aged 18 years or over) in the general population, primary care or hospital settings. Studies were included even if their description was not based on clear measurement criteria (eg, stating a 'significant increase in pain' but not the amount of change on a pain score this would equate to). Studies that included a mixed OA population (eg, knee or hip OA) and did not separately report knee-specific findings were included. There were no restrictions on study dates or design. All non-English language articles were translated to identify a flare definition. Theses, dissertations, book chapters and guidelines and animal studies were excluded. Conference abstracts were included if they contained a definition for an OA flare-up. Studies were excluded if the flare was induced by an iatrogenic source, for example, injection-induced flares,[@R21] as these may have been caused by a different pathophysiological process. Abstracts were included in this study as the main outcome of interest was the definition of flare used and it was decided that including abstracts would ensure a more comprehensive review. For each abstract, a search was conducted to identify a corresponding full-text paper. Where one was found only the full paper was included in the review.

The search and article retrieval was conducted by the first reviewer (ELP). Articles were downloaded into RefWorks bibliography and database manager (RefWorks Copyright 2009). Duplicates were removed and all titles were screened by ELP against inclusion criteria, with the first 20 titles checked by two reviewers (ELP and MJT) for consistency. For qualitative studies, all identified potentially eligible full-text articles were obtained.

All abstracts and then full-text articles were screened by two reviewers (ELP and MJT), with disagreements resolved by consensus adjudicated by a third reviewer (GP). Where articles could not be retrieved or if the flare definition used was not included in the text, contact with authors was made.

The final included articles were checked to ensure results were not duplicated, for example, where different authors were reporting on the same dataset, to reduce bias.[@R22] For articles containing pooled studies, the original studies were sought and included in the main analysis, where available. No full-text articles were required to be translated.

Data extraction {#s2b}
---------------

The following data pertaining to flares were extracted from full-text articles by the first reviewer: definition used for change in pain, pain scale used, duration of flare (for flare design trials we extracted the duration of the withdrawal period for comparison), associated symptoms, rationale behind definition used, terminology used (eg, exacerbation or flare), baseline OA severity, age range, gender, geographical location, number of participants and study design. Missing data were described in the data extraction tables.

Quality assessment of included studies {#s2c}
--------------------------------------

Our aim was to identify and contrast definitions of flare-ups used in the literature. We were not concerned with the methodological rigour of the studies deriving, evaluating or applying those definitions. However, for studies presenting definitions we sought supporting statements that gave the rationale for the definition.

Data analysis {#s2d}
-------------

A narrative synthesis was undertaken guided by the four-stage process of Popay *et al*.[@R22] This approach was chosen as it allowed the words and text in the definitions to be synthesised to summarise findings.[@R23] The initial data extracted were grouped into drug withdrawal studies ('flare design') and other studies. Frequencies of components included in definitions was tabulated, these included; terminology used, onset/worsening of symptoms; signs/symptoms above day-to-day variability/minimum threshold; speed of onset of symptoms; duration of worsening and change in medication/healthcare usage.

This initial tabulation helped identify similarities and differences and allowed themes to emerge. This was done with an inductive-type approach, where possible, that is, without an a priori assumption, and deductively acknowledging that the reviewers were clinicians, that is, they had some background knowledge of the topic of interest. This allowed further examination of the differences of definitions used in drug withdrawal and non-drug withdrawal study designs, and examination of key components of definitions used.

Patient and public involvement {#s2e}
------------------------------

There was no patient or public involvement in this study.

Results {#s3}
=======

Study selection {#s3a}
---------------

The literature search yielded 2194 articles, of which 786 were duplicates ([figure 1](#F1){ref-type="fig"}). After title screening, 336 abstracts were reviewed, 223 were not relevant for the study purpose. One hundred thirteen articles were examined in full, which resulted in a further 60 being excluded. The main reason for exclusion was no definition of flare-up reported in text (n=56). At this stage, a further 16 articles were identified from the reference lists of the retrieved full-text articles resulting in 69 included studies for synthesis.
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Study characteristics {#s3b}
---------------------

Characteristics of the included studies are described in [table 1](#T1){ref-type="table"}.[@R20] The number of participants in each study ranged from 15 to 6085.[@R20] Knee OA was defined by clinical and/or radiological criteria.

###### 

Characteristics of all included studies

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author, year of publication        Setting, geographic location                                                          Participants                                                                                                Joint           Severity                                                                                                                 Study design
  ---------------------------------------- ------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------- --------------- ------------------------------------------------------------------------------------------------------------------------ -----------------------------------------------------------------------------
  **Drug withdrawal design studies**                                                                                                                                                                                                                                                                                                                                                  

  Altman, 2015[@R24]                       Multicentre, recruitment not specified, USA                                           403 males and females, ≥40 years                                                                            Knee and hip    KL grade 2--3                                                                                                            RCT, flare design

  Baer, 2005[@R26]                         17 medical centres recruiting from community and physician private practice; Canada   216 males and females, 40--85 years                                                                         Knee            Radiographic evidence of OA (severity not defined)                                                                       RCT, flare design

  Baraf, 2011[@R27]                        Primary care, internal medicine, orthopaedic, rheumatology; USA                       602 males and females, ≥25 years                                                                            Knee            Radiographically mild to moderate (KL grade 1--3)                                                                        RCT, flare design

  Battisti, 2004[@R28]                     Clinical centres, outpatients; USA                                                    3980 males and females, ≥40 years (age unavailable for Geba 2003 and Weaver 2003)                           Knee            ACR functional class rating of I, II or III                                                                              RCT, pooled four trials, flare design

  Bingham, 2007[@R29]\                     2×74 outpatient clinics; USA                                                          1207 males and females, ≥40 years                                                                           Knee and hip    ARA functional capacity classification I--III                                                                            RCT, flare design
  Bingham, 2011[@R75]                                                                                                                                                                                                                                                                                                                                                                 

  Birbara, 2006[@R30]                      Investigative sites; USA                                                              808 males and females, ≥40 years                                                                            Knee            ARA functional class, I, II or III                                                                                       RCT, flare design

  Bocanegra, 1998[@R31]                    Clinic; USA                                                                           572 males and females, 28--88 years (mean 61--62)                                                           Knee and hip    ARA functional capacity classification I--III                                                                            RCT, flare design

  Boswell, 2008[@R32]                      50 centres (Europe and Australia)+187 centres (Europe and USA)                        1908 males and females, ≥40 years                                                                           Knee            KL scale 2 or 3 and ARA class rating of I, II or III                                                                     Pooled RCTs (2; one flare design, one non-flare), flare design

  Brandt, 2006[@R33] (pilot studies)       Community; USA                                                                        30 males and females, mean age 62 years                                                                     Knee            KL≥2                                                                                                                     Cohort design, flare design

  Case, 2003[@R34]                         Hospital-rheumatology centre; Chicago, USA                                            82 males and females, 40--75 years                                                                          Knee            KL≥1, and clinical criteria (pre-enrolment ambulatory pain); moderate pain by a 5-point Likert scale or increased pain   RCT, flare design

  Day, 2000[@R73]                          49 investigative sites in 26 countries                                                809 males and females, mean age range 62--65 years                                                          Knee and hip    ARA functional class I--III, symptomatic for at least 6 months                                                           RCT, flare design

  Ehrich, 1999[@R35]                       Clinical centres; USA                                                                 219 males and females, \>40 years                                                                           Knee            ARA functional class, I, II or III                                                                                       RCT, flare design

  Essex, 2012[@R36]                        Clinical centre; African-American, USA                                                322 males and females, ≥45 years                                                                            Knee            ARA functional capacity classification I--III                                                                            RCT, flare design

  Essex 2013[@R76]                         Hispanic population, 31 US centres                                                    ≥45 years                                                                                                   Knee            ACR criteria, functional capacity classification I--III                                                                  RCT, flare design

  Gibofsky, 2014[@R37]                     Not specified, USA                                                                    305 males and females, 41--90 years                                                                         Knee and hip    KL 2--3                                                                                                                  RCT, flare design

  Gineyts, 2004[@R38]                      Subset of larger study; France                                                        201 males and females, mean age 61--62 years                                                                Knee and hip    ARA I--III                                                                                                               RCT, flare design

  Goldberg, 1988[@R39]                     Investigative sites; USA                                                              214 males and females, 40--85 years (mean 64)                                                               Knee and hip    Radiographic evidence of knee OA, not further defined                                                                    RCT, flare design

  Gottesdiener, 2002[@R40]                 Investigative sites; USA                                                              617 males and females, ≥40 years                                                                            Knee            ARA functional class I--III                                                                                              RCT, flare design

  Hochberg, 2011[@R41]                     Centres; USA                                                                          1234 males and females, ≥50 years                                                                           Knee            ACR functional class I--III                                                                                              Pooled RCTs (2), flare design

  Katz, 2010[@R42]                         Clinical sites; USA                                                                   113 males and females, 28--83 years (median 57)                                                             Knee and hip    OA of hip and knee as diagnosed using ACR criteria, no definition of severity                                            RCT, flare design

  Kivitz, 2001[@R43]                       Investigative sites; USA                                                              491 males and females, 28--91 years (mean 58--61)                                                           Knee            Confirmation of OA on weight-bearing radiograph, no definition of severity                                               RCT, flare design

  Kivitz, 2004[@R74]                       Outpatient sites; USA                                                                 1042 males and females, ≥40 years                                                                           Knee            ACR rating of I--III                                                                                                     RCT, flare design

  Leung, 2002[@R45]                        Clinic; USA                                                                           677 males and females, ≥40 y                                                                                Knee and hip    ARA functional class, I, II, or III                                                                                      RCT, flare design

  Luyten, 2007[@R45]                       Centres; Belgium                                                                      181 males and females, ≥40 years                                                                            Knee and hip    ACR functional capacity classification I--III                                                                            RCT, flare design

  Manicourt, 2005[@R47]                    Outpatient clinic; Belgium                                                            90 males and females, 50--81 years (mean 63--67)                                                            Knee and hip    Clinical and radiographic evidence of OA, severity not defined                                                           RCT, flare design

  Mazzuca, 2002[@R48]                      Not specified, USA                                                                    15 males and females, ≥45 years                                                                             Knee            KL 2--3                                                                                                                  Observational, flare design

  McIlwain, 1989[@R49]                     Investigative sites; USA                                                              139 males and females, mean 65 years                                                                        Knee            Radiological evidence of moderate or severe osteoarthritis, not further defined                                          RCT, flare design

  Mendelsohn, 1991[@R50]                   Investigative sites; USA                                                              139 males and females, 21--88 years (mean age 63.3 years)                                                   Knee            Radiological evidence of moderate or severe osteoarthritis, not further defined                                          RCT, flare design

  Moskowitz, 2006[@R51]                    Investigative sites; USA                                                              530 males and females, ≥45 years                                                                            Knee            ACR functional capacity classification I--III                                                                            RCT, flare design

  Pareek, 2009[@R52]                       Multicentre study, India                                                              199 males and females, 40--70 years                                                                         Knee            Lequesne criteria, score of 5 and above                                                                                  RCT, flare design

  Pareek, 2010[@R53]                       Hospital; India                                                                       220 males and females, 40--70 years                                                                         Knee            Clinical and radiological evidence of OA severity not defined                                                            RCT, flare design

  Roth, 2004[@R88]                         Physicians private practice or community; USA                                         326 males and females, 40--85 years                                                                         Knee            Radiological evidence of OA, severity not defined                                                                        RCT, flare design

  Rother, 2007[@R91]                       Outpatient units; Germany                                                             397 males and females, ≥ 40 years                                                                           Knee            KL 2--3                                                                                                                  RCT, flare design

  Schnitzer, 2005[@R55]                    Investigative sites; International (seven countries)                                  583 males and females, 18--75 years                                                                         Knee and hip    Diagnosis based on ACR criteria, severity not defined                                                                    RCT, flare design

  Scott-Lennox, 2001[@R56]                 Investigative sites; USA                                                              182 males and females, mean age 61 years                                                                    Knee            Not defined                                                                                                              RCT, flare design

  Silverfield, 2002[@R57]                  Centres; USA                                                                          308 males and females, 35--75 years                                                                         Knee and hip    Clinical evidence of OA, severity not defined                                                                            RCT, flare design

  Simon, 2009[@R89]                        Outpatient centres; Canada, USA                                                       775 males and females, 40--85 years                                                                         Knee            Clinical and radiological evidence of OA, severity not defined                                                           RCT, flare design

  Strand, 2011[@R58]                       Investigative sites; multinational---not specified including USA                      875 males and females, 18--80 years                                                                         Knee and hip    OA according to ACR criteria and requiring NSAID treatment to control symptoms in the month preceding screening          RCT, flare design

  Weaver, 1995[@R90]                       Investigative sites; USA                                                              328 males and females, \>50 years                                                                           Knee            ACR clinical criteria, diagnostic                                                                                        RCT, flare design

  Wiesenhutter, 2005[@R59]                 Medical centres; USA                                                                  528 males and females, 40--89 years                                                                         Knee and hip    ARA functional class I, II or III                                                                                        RCT, flare design

  Williams, 2001[@R60]                     Clinical sites; USA                                                                   718 males and females, mean age 61--62 years                                                                Knee            ACR clinical and radiographic criteria I--III                                                                            RCT, flare design

  Wittenberg, 2006[@R61]                   Centres (not specified); Germany                                                      364 males and females, 50 years                                                                             Knee            Moderate-to-severe symptomatic OA of the knee according to ACR criteria                                                  RCT, flare design

  Yeasted, 2014[@R62] (poled, abstract)    USA                                                                                   219 (merged observational), 137 (merged trial) \>40 years                                                   Not specified   ACR criteria, diagnostic                                                                                                 Two longitudinal observational studies, placebo arms of two clinical trials

  Yocum, 2000[@R77]                        USA, 62 study centres                                                                 774 males and females, ≥40 years                                                                            Knee or hip     Diagnosis confirmed by XR and clinical symptoms (not further specified)                                                  RCT, flare design

  Young, 2014[@R63] (abstract)             Multicentre                                                                           305 males and females, \>40 years                                                                           Knee or hip     KL 2--3                                                                                                                  RCT, flare design

  Zhao, 1999[@R64]                         Centre (not specified); USA, Canada                                                   1004 males and females, ≥18 years                                                                           Knee            ACR functional capacity classification I--III                                                                            RCT, flare design

  **Non-drug withdrawal design studies**                                                                                                                                                                                                                                                                                                                                              

  Atukorala, 2016[@R78] (abstract)\        Not specified, USA+Australia+Sri Lanka                                                213 males and females, mean age 62 years\                                                                   Knee            Not specified                                                                                                            3-month, web-based longitudinal follow-up study
  Atukorala, 2016[@R25]\                                                                                                         345 males and females, mean age 62 years                                                                                                                                                                                                             
  (abstract)                                                                                                                                                                                                                                                                                                                                                                          

  Bartholdy, 2016[@R79]                    OA outpatient clinic, Denmark                                                         131 males and females, ≥40 years                                                                            Knee            Radiographic evidence of OA (severity no defined) and BMI between 20 and 35 kg/m^2^                                      RCT

  Bassiouni 2015[@R80] (abstract)          Not specified, Egypt                                                                  60 participants not further specified                                                                       Knee            Not specified                                                                                                            Observational

  Cibere, 2004[@R86]\                      Community, Canada                                                                     137 males and females, mean age 65 years (43--88) for placebo and 64 years (40--83) for glucosamine group   Knee            KL≥2 on anteroposterior radiograph                                                                                       RCT
  Cibere, 2005[@R87]                                                                                                                                                                                                                                                                                                                                                                  

  Conrozier 2012[@R66]                     Hospital-rheumatology unit, France                                                    44 males and females, mean age 67.6 years                                                                   Knee            Radiographic evidence of knee OA, not further defined                                                                    Observational

  D'Agostino 2005[@R67]                    Hospital-European multicentre                                                         600 males and females, ≥18 years                                                                            Knee            KL grade 1--4                                                                                                            Observational

  Erfani, 2014[@R44] (abstract)\           Australia                                                                             268 males and females, mean age 62 years\                                                                   Knee            ACR criteria, meet at least one, KL≥2                                                                                    Web-based crossover
  Erfani, 2014[@R81] (abstract)\                                                                                                 345 males and females, ≥40 years                                                                                                                                                                                                                     
  Ferreira, 2016[@R82]\                                                                                                                                                                                                                                                                                                                                                               
  Hunter, 2014[@R83] (abstract)\                                                                                                                                                                                                                                                                                                                                                      
  Makovey, 2015[@R84] (protocol)                                                                                                                                                                                                                                                                                                                                                      

  Jawad, 2005[@R68]                        GPs in France                                                                         3000 (for GP study) males and females                                                                       Knee            Not defined                                                                                                              n/a, review of surveys. Definition relates to survey of 3000 French GPs

  Marty 2009[@R20]                         Community and hospital, France                                                        6085+641 males and females, mean age 66.4 years (10.9) for flare group, 66.2 years (10.2) no flare group    Knee            OA diagnosis based on ACR criteria, severity not defined                                                                 Observational

  Murphy, 2015[@R69]                       Community based, pain clinics; USA                                                    45 males and females, 37--83 years                                                                          Knee            ACR criteria, severity not defined                                                                                       Qualitative

  Parry, 2017[@R85]                        Community, UK                                                                         719 males and females, ≥50 years                                                                            Knee            Self-reported knee pain in previous 12 months                                                                            Observational

  Ricci 2005[@R54]                         Community, USA                                                                        329 males and females, 40--65 years                                                                         Knee and hip    Clinical evidence of OA, severity not defined                                                                            Nested case-control

  Wise 2010[@R70]                          Primary care, hospital, USA                                                           303 males and females, ≥50 years                                                                            Knee and hip    Signal joint pain in a hip or knee on at least 15 out of the 30 days prior to enrolment, not further defined             Observational

  Zhang 2009[@R71]                         Primary care, hospital, USA                                                           303 males and females, ≥50 years                                                                            Knee and hip    Signal joint pain in a hip or knee on at least 15 out of the 30 days prior to enrolment, not further defined             Observational

  Zhang 2011[@R72] (abstract)              Not specified                                                                         52 males and females, median age 63 years (50--72 years)                                                    Knee            KL\>2                                                                                                                    Case-crossover

  Zobel 2016[@R92]                         Hospital databases, Australia                                                         297 males and females, \>40 years                                                                           Knee            ACR criteria, KL≥2 or patellofemoral OA on radiograph                                                                    Web-based case-crossover
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ACR, Arthritis Center Research; ARA, American Rheumatism Association; GP, general practitioner; KL, Kellgran and Lawrence; RCT, randomised controlled trial.

Twenty-one included mixed knee and hip OA groups.[@R24] In total, 46 publications used a drug withdrawal RCT design,[@R24] 4 of which were pooled studies[@R28] and 1 used a cohort drug withdrawal design[@R33] ([table 1](#T1){ref-type="table"}). The remaining 22 publications included 17 observational studies,[@R20] 3 RCTs,[@R79] 1 survey[@R68] and 1 qualitative interview study.[@R69] Nine of the included studies were abstracts.[@R25] Two abstracts were removed as the corresponding full-text article was available.[@R69] Studies using pooled data or the same dataset were included if they used different definitions of OA flare.[@R28]

Rationale given for flare definitions {#s3c}
-------------------------------------

Six of the included studies gave rationale for the definition used.[@R20] None of the definitions was based on a consensus procedure. The studies by Marty *et al*[@R20] and Scott-Lennox *et al*[@R56] were the only ones that undertook empirical investigation of flare definitions. The study by Marty *et al*[@R20] was the only study specifically designed to validate a diagnostic tool for knee OA flares. Potential factors associated with flare-ups were identified, for example, knee swelling and the authors used a logistic regression analysis to assign a weight to each of the items identified. A flare-up score was determined using a general practitioner database and this was then validated using a rheumatologist database. Pain was not included in the final model.

Scott-Lennox *et al*[@R56] sought to test whether four measures for flare intensity (patient's self-assessment of pain scores, physician's assessment of pain scores, patient's global OA assessment and physician's global OA assessment) could be combined to form a reliable and valid index using data from an RCT using a confirmatory factor analysis. The authors produced three flare intensity groups (low, moderate and severe) and highlighted how these could be used to examine treatment effects.

Cibere *et al*[@R86] outlined face validity checks. It was specified that the flare definition had been determined by study rheumatologists to be a clinically important change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score. The definition used by Murphy *et al*[@R69] was informed by two studies,[@R28] which used a drug withdrawal design and from the research team's own experience. Ricci *et al*[@R54] used a combination of data-driven and clinical judgement approaches to establish an agreed cut point. Parry *et al* based their definition on OA flare design studies and flare definitions used in other chronic disease such as back pain and COPD.

Flare definitions in drug withdrawal studies {#s3d}
--------------------------------------------

### Terminology used {#s3d1}

The majority of publications using a drug withdrawal design used the term 'flare' in their description[@R24] (n=42; [table 2](#T2){ref-type="table"}).

###### 

Definition, terminology and measurement instruments used in all included studies

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author                            Terminology used                     Amount of change in symptoms/signs (symptom/sign: measurement instrument; operational definition)                                                                                                                                                                                                                               Minimum absolute level of symptoms/signs (symptom/sign: measurement instrument; operational definition)                                                                                                                                                                                                                                     Speed of onset                                                      Duration                   Change in medication/healthcare use                                                 Reference/rationale
  --------------------------------------- ------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------- -------------------------- ----------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------
  **Drug withdrawal study design**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Altman[@R24]                            'Flare'                              *Pain*: WOMAC Pain subscale (0--100); increase≥15 mm                                                                                                                                                                                                                                                                            *Pain:* WOMAC Pain subscale; ≥40 mm                                                                                                                                                                                                                                                                                                         Not specified                                                       Not specified              Not specified                                                                       None

  Baer 2005[@R26]                         'Flare'                              *Pain:* WOMAC LK3.1 Pain subscale (0--20); increase≥2 points and ≥25%                                                                                                                                                                                                                                                           *Pain:* WOMAC Pain score (0--20); ≥6 and ≥1 item rated 'moderate, severe or extreme'                                                                                                                                                                                                                                                        Interval between screening and baseline remeasurement unclear       Not specified              Not specified                                                                       None

  Baraf 2011[@R27]                        'Flare'                              *Pain on movement:* VAS (0--100 mm); increase≥5 mm                                                                                                                                                                                                                                                                              Not specified                                                                                                                                                                                                                                                                                                                               1 week washout                                                      Not specified              Not specified                                                                       None

  Battisti 2004[@R28]                     'Flare'                              *Global assessment (investigator):* single item, 5-point LK; worsening≥1 point                                                                                                                                                                                                                                                  *Pain:* VAS (0--100 mm); ≥40 mm                                                                                                                                                                                                                                                                                                             Not specified                                                       Not specified              Not specified                                                                       None

  Bingham 2007[@R29]\                     'Flare'                              *Pain walking on flat surface:* WOMAC VAS 3.0 Q1 (0--100 mm); increase≥15 mm*Global assessment of disease status (investigator):* single item, 5-point LK; worsening≥1 point                                                                                                                                                    *Pain walking on flat surface:* ≥40 mm on WOMAC VAS 3.0 Q1 (0--100)*Global assessment (investigator)*: single item, 5-point LK; fair, poor, very poor (*acetaminophen users only*)*Global assessment of disease status (patient):* VAS 0--100 mm; ≥40 mm (*acetaminophen users only*)                                                       Not specified                                                       Not specified              Not specified                                                                       None
  Bingham 2011[@R75]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Birbara 2006[@R30]                      'Flare'                              *Pain walking on flat surface:* WOMAC VAS Q1 (0--100 mm); increase≥15 mm*Global assessment (investigator):* single item, 5-point LK; worsening≥1 point                                                                                                                                                                          *Pain walking on flat surface:* WOMAC VAS 3.0 Q1 (0--100); ≥40 mm*Global assessment (investigator):* single item, 5-point LK; fair, poor or very poor (*paracetamol arm only*)                                                                                                                                                              4--15 days washout                                                  Not specified              Not specified                                                                       None

  Bocanegra 1998[@R31]                    'Worsening of symptoms'              Two out of the following three:*Global assessment (physician):* single item, 5-point LK; increase≥1 grade*Global assessment (patient):* patients global assessment (current symptoms and limitation of activity) 5-point LK; increase≥1 grade*Composite index:* Lequesne OA Severity Index (0--24); increase≥2 points           *Global assessment (physician):* single item, 5-point LK; 'poor/very poor'*Global assessment (patient):* patients global assessment (current symptoms and limitation of activity) 5-point LK; 'poor/very poor'*Composite index:* Lequesne OA Severity Index (0--24); ≥7                                                                     3--14 days washout                                                  Not specified              Not specified                                                                       None

  Boswell 2008[@R32]                      'Flare'                              *Pain walking on flat surface:* WOMAC VAS Q1 (0--100 mm); increase≥15 mm*Global assessment (patient):* Patient Global Assessment of Arthritis Condition (PGAC) (unspecified); worsening≥1 point                                                                                                                                 Not specified                                                                                                                                                                                                                                                                                                                               Not specified                                                       Not specified              Not specified                                                                       None

  Brandt 2006[@R33] (pilot studies)       'Flare'                              Not specified                                                                                                                                                                                                                                                                                                                   *Pain:* WOMAC LK Pain subscale (5--25); ≥15 points                                                                                                                                                                                                                                                                                          Five half-lives of NSAID washout                                    Not specified              Not specified                                                                       None

  Case 2003[@R34]                         Not used                             *Pain walking on flat surface:* VAS (0--100 mm); increase≥10 mm*Ambulatory pain*; 5-point LK; worsening≥1 point                                                                                                                                                                                                                 Not specified                                                                                                                                                                                                                                                                                                                               14 days washout                                                     Not specified              Not specified                                                                       None

  Day 2000[@R73]                          Not used                             *Pain walking on a flat surface:* WOMAC VAS Q1 (0--100 mm); increase≥15 mm*Global Assessment (investigator):* single item, 5-point LK; worsening≥1 point*Global assessment (patient):* VAS (0--100 mm); increase≥15 mm (*acetaminophen users only*)                                                                             *Pain walking on a flat surface:* WOMAC VAS Q1 (0--100 mm); ≥40 mm*Global Assessment (investigator):* single item, 5-point LK; 'fair, poor or very poor'*Global Assessment (patient):* VAS (0--100 mm); ≥40 mm                                                                                                                              Longer than five plasma half-lives washout                          Not specified              Not specified                                                                       None

  Ehrich 1999[@R35]                       Not used                             *Pain:* VAS (0--100 mm); increase≥15 mm                                                                                                                                                                                                                                                                                         *Pain:* VAS (0--100 mm); ≥40 mm                                                                                                                                                                                                                                                                                                             Longer than five plasma half-lives washout of NSAID                 Not specified              Not specified                                                                       None

  Essex 2012[@R36]                        'Flare'                              *Global Assessment (physician):* 5-point LK; increase≥1 grade*Global Assessment (patient):* 5-point LK; increase≥1 grade                                                                                                                                                                                                        *Global Assessment (physician):* 5-point LK; 'fair, poor or very poor'*Global Assessment (patient):* 5-point LK; 'fair, poor or very poor'*Pain:* VAS (0--100 mm); 40--90 mm                                                                                                                                                                48 hours withdrawal                                                 Not specified              Not specified                                                                       None

  Essex 2013[@R76]                        'Flare'                              Not specified                                                                                                                                                                                                                                                                                                                   *Global Assessment of arthritis (physician):* Minimum rating of 3*Global Assessment of arthritis (patient):* Minimum rating of 3*Pain:* VAS (0--100 mm); 40--90 mm                                                                                                                                                                          48 hours withdrawal                                                 Not specified              Not specified                                                                       None

  Gibofksy 2014[@R37]                     'Flare'                              *Pain:* WOMAC Pain VAS; increase≥15 mm                                                                                                                                                                                                                                                                                          *Pain:* WOMAC Pain VAS; ≥40 mm                                                                                                                                                                                                                                                                                                              Not specified                                                       Not specified              Not specified                                                                       None

  Gineyts 2004[@R38]                      'Flare'                              *Pain walking on a flat surface:* WOMAC VAS Q1 (0--100 mm); increase≥15 mm*Global Assessment (investigator):* 5-point scale: worsening≥1 point                                                                                                                                                                                  *Pain walking on a flat surface:* WOMAC VAS Q1 (0--100 mm); ≥40 mm                                                                                                                                                                                                                                                                          five half-lives of NSAID washout                                    Not specified              Not specified                                                                       None

  Goldberg 1988[@R39]                     'Flare'                              *Pain:* Investigator assessed pain grade (none/mild/mod/severe): (i) at rest, (ii) on passive motion, (iii) on palpation, (iv) weight bearing; increase≥1 grade in two items OR increase≥2 grade in one item                                                                                                                    Not specified                                                                                                                                                                                                                                                                                                                               2--14 days washout until flare                                      Not specified              Not specified                                                                       None

  Gottesdiener 2002[@R40]                 'Flare'                              *Pain on walking*: VAS (0--100 mm); increase≥15 mm*Global Assessment (investigator):* 5-point LK; increase≥1 point                                                                                                                                                                                                              *Pain on walking*: VAS (0--100 mm); ≥40 mm                                                                                                                                                                                                                                                                                                  3--15 days washout                                                  Not specified              Not specified                                                                       None

  Hochberg 2011[@R41]                     'Flare'                              *Pain walking on a flat surface:* WOMAC VAS Q1 (0--100 mm); increase≥15 mm*Global Assessment (patient):* 5-point LK; worsening≥1 point                                                                                                                                                                                          *Pain walking on a flat surface:* WOMAC VAS Q1 (0--100 mm); ≥40 mm                                                                                                                                                                                                                                                                          Not specified                                                       Not specified              Not specified                                                                       None

  Katz 2010[@R42]                         'Flare'                              Not specified                                                                                                                                                                                                                                                                                                                   *Pain:* pain score (0--10); ≥5                                                                                                                                                                                                                                                                                                              Not specified-washout until flare occurred                          Not specified              Not specified                                                                       None

  Kivitz 2001[@R43]                       'Flare'                              *Pain:* Patients Assessment of Pain Score (0--10) (unspecified); increase≥2 points                                                                                                                                                                                                                                              *Pain:* Patients Assessment of Pain Score (0--10) (unspecified); ≥5                                                                                                                                                                                                                                                                         Five drug half-lives or 48 hours                                    Not specified              Not specified                                                                       None

  Kivitz 2004[@R74]                       'Flare'                              *Pain on walking:* VAS (0--100 mm); worsening≥15 mm*Global Assessment (investigator)*: 5-point LK; worsening≥1 point                                                                                                                                                                                                            Not specified                                                                                                                                                                                                                                                                                                                               NSAID-dependent half-life washout                                   Not specified              Not specified                                                                       None

  Leung 2002[@R45]                        'Flare'                              *Pain on walking on a flat surface:* WOMAC VAS Q1 (0--100 mm); increase≥15 mm*Global Assessment (investigator):* 5-point LK; worsening≥1 point                                                                                                                                                                                  *Pain on walking on a flat surface:* WOMAC VAS Q1 (0--100 mm); ≥40 mm*Global Assessment (patient):* (0--100 mm); ≥40 mm (*acetaminophen users only*)*Global Assessment (investigator):* 5-point LK; 'fair, poor or very poor' (*acetaminophen users only*)                                                                                  Determined by drug half-life washout                                Not specified              Not specified                                                                       None

  Luyten 2007[@R46]                       'Flare'                              *Global Assessment (patient):* 5-point LK; increase≥1 grade*Global Assessment (physician):* 5-point LK; increase≥1 grade*Composite definition:* Lequesne Osteoarthritis Severity Index (0--24); increase≥2 points                                                                                                               *Global Assessment (patient):* 5-point LK; 'fair, poor or very poor' (*not on treatment---'poor or very poor'*)*Global Assessment (physician):* 5-point LK; 'fair, poor or very poor'(*Not on treatment--- 'poor or very poor'*)*Composite definition:* Lequesne Osteoarthritis Severity Index (0--24); ≥7*Pain:* VAS (0--100 mm); ≥40 mm   2--14 days washout                                                  Not specified              Not specified                                                                       None

  Manicourt 2005[@R47]                    'Flare'                              *Pain when walking on a flat surface:* VAS (0--100 mm); ≥10 mm                                                                                                                                                                                                                                                                  Not specified                                                                                                                                                                                                                                                                                                                               7--10 days washout                                                  Not specified              Not specified                                                                       None

  Mazzuca 2002[@R48]                      'Flare'                              *Pain on standing*: WOMAC LK Pain Q5 'severe or extreme' after the washout AND decreased after resumption of usual analgesic drugs and/or NSAIDs                                                                                                                                                                                Not specified                                                                                                                                                                                                                                                                                                                               Drug washout five half-lives                                        Not specified              Not specified                                                                       None

  McIlwain 1989[@R49]                     'Flare'                              No measurement instrument: increase in pain on motion, swelling, tenderness, redness and/or heat (unspecified if patient/physician/investigator reported)                                                                                                                                                                       Not specified                                                                                                                                                                                                                                                                                                                               2--14 days washout                                                  Not specified              Not specified                                                                       None

  Mendelsohn 1991[@R50]                   'Worsening of arthritis condition'   *Pain:* Pain scale (0--3) (0=none, 3=severe); worsening score*Global (physician):* (0--100); worsening score                                                                                                                                                                                                                    Not specified                                                                                                                                                                                                                                                                                                                               Up to 14 days washout                                               Not specified              Not specified                                                                       None

  Moskowitz 2006[@R51]                    'Flare'                              *Global assessment (patient):* 5-point LK; increase≥1 grade*Global Assessment (physician)*: 5-point LK; ≥1 grade increase*Composite index:* Lequesne OA Severity Index (0--24); increase≥2 points                                                                                                                               *Global assessment (patient):* 5-point LK; '(fair), poor or very poor'*Global Assessment (physician):* 5-point LK; '(fair), poor or very poor'*Composite index*: Lequesne OA Severity Index (0--24); minimum≥7*Pain walking on a flat surface:* VAS (0--100 mm); ≥40 mm                                                                     NSAID washout of five half-lives or at least 2 days                 Not specified              Not specified                                                                       None

  Pareek 2009[@R52]                       'Flare-up'                           *Pain:* 11-point NRS; increase≥2 points during previous 2--5 daysSigns and symptoms suggestive of inflammation, morning stiffness and nocturnal pain interfering with sleep                                                                                                                                                     *Pain:* pain intensity of at least 4 on a 11-point NRS during physical activity for past 24 hours                                                                                                                                                                                                                                           Placebo washout for 24--48 hours                                    2--5 days                  Not specified                                                                       None

  Pareek 2010[@R53]                       'Flare'                              Flare symptoms noted but not part of definition: morning stiffness, erythema, nocturnal pain and swelling/inflammation                                                                                                                                                                                                          *Pain with physical activity*: VAS 0--10; ≥6*Composite index:* WOMAC total LK; ≥25.*Composite index*: Lequesne OA Severity Index (0--24); ≥5                                                                                                                                                                                                Not specified                                                       2--5 days                  Not specified                                                                       None

  Roth 2004[@R88]                         'Flare'                              *Pain:* WOMAC LK3.1 Pain subscale (0--20); increase≥2 points and ≥25%                                                                                                                                                                                                                                                           *Pain:* WOMAC LK3.1 Pain subscale (0--20); score ≥ 'moderate' on at least 1 of the five items, pain score≥6                                                                                                                                                                                                                                 Washout period of at least 3 days/week past month                   Not specified              Not specified                                                                       None

  Rother 2007[@R91]                       'Flare'                              *Pain on walking:* VAS (0--100 mm); increase≥15 mm*Global Assessment (patient):* 5-point LK; increase≥1 grade                                                                                                                                                                                                                   *Pain on walking:* VAS (0--100 mm); ≥40 mm*Global Assessment (patient):* 5-point LK; 3--5                                                                                                                                                                                                                                                   Not specified                                                       Not specified              Not specified                                                                       None

  Schnitzer 2005[@R55]                    'Flare'                              No tool: increase in pain                                                                                                                                                                                                                                                                                                       *Pain:* VAS (0--100 mm); ≥40 mm                                                                                                                                                                                                                                                                                                             Not specified                                                       24 hours                   Not specified                                                                       None

  Scott-Lennox 2001[@R56]                 'Flare'                              *Pain:* VAS (0--100 mm); ≥20 mm*Pain (physician):* 4-point LK; worsening≥1 point*Global Assessment (patient):* 4-point LK; worsening≥1 point*Global Assessment (physician)*: 4-point LK; worsening≥1 point                                                                                                                      *Pain:* VAS (0--100 mm); ≥40 mm at baseline)*Pain (physician):* 4-point LK; ≥2*Global Assessment (patient):* 4-point LK; ≥2*Global Assessment (physician)*: 4-point LK; worsening≥2                                                                                                                                                         14 days washout                                                     Not specified              Not specified                                                                       Confirmatory Factor Analysis

  Simon 2009[@R89]                        'Flare'                              *Pain:* WOMAC LK3.1 Pain subscale; increase≥2 and ≥25%                                                                                                                                                                                                                                                                          *Pain:* WOMAC LK3.1 Pain subscale; ≥ 'moderate' on ≥1 item                                                                                                                                                                                                                                                                                  14 days washout                                                     Not specified              Not specified                                                                       None

  Silverfield 2002[@R57]                  'Flare'                              *Pain:* no measurement tool; significant increase                                                                                                                                                                                                                                                                               Not specified                                                                                                                                                                                                                                                                                                                               Not specified                                                       Not specified              Pain requiring supplemental analgesic medication and/or an increase in NSAID dose   None

  Strand 2011[@R58]                       'Flare'                              *Global Assessment (patient):* 5-point LK; increase≥1                                                                                                                                                                                                                                                                           *Global Assessment (patient):* 5-point LK; 'fair, poor or very poor'*Pain*: (0--10 NRS); ≥4 but \<9*Global Assessment (physician)*: 5-point LK; 'fair, poor or very poor'                                                                                                                                                                   14 days washout                                                     Not specified              Not specified                                                                       None

  Weaver 1995[@R90]                       'Flare'                              *Global Assessment (physician)*: 5-point Likert; increase≥1 grade*Global Assessment (patient)*: 5-point LK; increase≥1 grade*Pain:* worsening pain on motion and weight bearing                                                                                                                                                 *Global Assessment (physician):* 5-point Likert; ≥2*Global Assessment (patient)*: 5-point LK; ≥2                                                                                                                                                                                                                                            2--14 days washout                                                  Not specified              Not specified                                                                       None

  Wiesenhutter 2005[@R59]                 'Flare'                              *Pain on walking on flat surface:* WOMAC VAS 3.0 Q1 (0--100 mm); increase≥15 mm*Global Assessment (investigator):* 5-point LK; worsening≥1 unit                                                                                                                                                                                 *Pain on walking on flat surface:* WOMAC VAS 3.0 Q1 (0--100 mm); ≥40 mm                                                                                                                                                                                                                                                                     Not specified                                                       Not specified              Not specified                                                                       None

  Williams 2001[@R60]                     'Flare'                              *Global Assessment (patient):* 5-point LK; increase≥1 point*Global Assessment (physician)*: 5-point LK; increase≥1 point*Composite Index*: Lequesne OA Severity Index (0--24); increase≥2 points                                                                                                                                *Global Assessment (patient):* 5-point LK; '(fair), poor or very poor'*Global Assessment (physician)*: 5-point LK; '(fair), poor or very poor'*Composite Index*: Lequesne OA Severity Index (0--24); ≥7*Pain:* VAS (0--100 mm); ≥40 mm                                                                                                      2--14 days                                                          Not specified              Not specified                                                                       None

  Wittenberg 2006[@R61]                   'Flare'                              *Pain:* VAS (0--100 mm); increase≥10 mm                                                                                                                                                                                                                                                                                         *Pain:* VAS (0--100 mm); ≥40 mm                                                                                                                                                                                                                                                                                                             2--7 days washout                                                   Not specified              Not specified                                                                       None

  Yeasted 2014[@R62] (pooled, abstract)   'Flare'                              *Pain:* 0--10 NRS; increase≥2 points over the mean pain score from the previous 3 days                                                                                                                                                                                                                                          *Pain:* average daily 0--10 NRS; 4--9                                                                                                                                                                                                                                                                                                       Not specified                                                       Not specified              Not specified                                                                       None

  Yocum 2000[@R77]                        'Flare'                              Disease activity*Global (Investigator)*: reduction of ≥1 grade*Global Assessment (patient)*: 100 mm VAS; increase of ≥10 mm*Pain: overall assessment (patient):* 100 mm VAS; ≥35 mm                                                                                                                                             Not specified                                                                                                                                                                                                                                                                                                                               ≥3 days washout                                                     Not specified              Not specified                                                                       None

  Young 2014[@R63]                        'Flare'                              \(3\) *Pain:* WOMAC pain subscale; increase\>15 mm                                                                                                                                                                                                                                                                              *Pain:* WOMAC Pain subscale\>40 mm                                                                                                                                                                                                                                                                                                          Not specified                                                       Not specified              Not specified                                                                       None

  Zhao 1999[@R64]                         'Flare'                              No measurement tool: worsening of signs and symptoms after discontinuation of NSAIDs of analgesics                                                                                                                                                                                                                              Not specified                                                                                                                                                                                                                                                                                                                               2--7 days washout                                                   Not specified              Not specified                                                                       None

  **Non-drug withdrawal study design**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Atukorala 2016[@R78] (abstract)\        'Flare'                              *Pain:* (10-point NRS); increase\>2 points from the mildest knee OA pain intensity reported at day 0                                                                                                                                                                                                                            Not specified                                                                                                                                                                                                                                                                                                                               Not specified                                                       Not specified              Not specified                                                                       None
  Atukorala 2016[@R25]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  (abstract)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Bartholdy 2016[@R79]                    'Flare'                              Not specified                                                                                                                                                                                                                                                                                                                   *Pain:* (10-point NRS): Pain\>5                                                                                                                                                                                                                                                                                                             Not specified                                                       Not specified              Not specified                                                                       None

  Bassiouni 2015[@R80] (abstract)         'Flare'                              Not specified                                                                                                                                                                                                                                                                                                                   *Global Assessment (physician):* KOFUS≥7                                                                                                                                                                                                                                                                                                    Not specified                                                       Not specified              Not specified                                                                       None

  Cibere 2004[@R86]\                      'Flare'                              Patients perception of worsening of symptoms*Pain walking on flat surface:* WOMAC VAS 3.0 Q1 (0--100 mm); increase≥20 mm*Global Assessment (physician):* 5-point LK; worsening≥1 grade                                                                                                                                          Not specified                                                                                                                                                                                                                                                                                                                               Not specified                                                       Not specified              Not specified                                                                       Definition determined by study rheumatologists to be a clinically important change in WOMAC-Ehrich 2000/Bellamy 1998
  Cibere 2005[@R87]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Conrozier 2012[@R66]                    'Flare'                              Fulfilled four following criteria:*Pain:* no measurement tool; 'sudden aggravation of knee pain'Causing nocturnal awakeningsClinical evidence of effusion                                                                                                                                                                       Not specified                                                                                                                                                                                                                                                                                                                               Sudden aggravation of knee pain, whose beginning was identifiable   Not specified              Not specified                                                                       None

  D'Agostino 2005[@R67]                   'Flare'                              Not specified                                                                                                                                                                                                                                                                                                                   *Pain intensity during physical activity:* VAS (0--100 mm); ≥40 mm                                                                                                                                                                                                                                                                          Not specified                                                       48 hours                   Not specified                                                                       None

  Erfani 2014[@R44] abstract)\            Exacerbation                         *Pain:* VAS (0--100 mm); increase≥20 mm from mildest pain score reported at baseline                                                                                                                                                                                                                                            Not specified                                                                                                                                                                                                                                                                                                                               Not specified                                                       Not specified              Not specified                                                                       None
  Erfani 2014[@R81] (abstract)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Ferreira 2016[@R82]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Hunter 2014[@R83] (abstract)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Makovey 2015[@R84] (protocol)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Jawad 2005[@R68]                        Exacerbation                         *Pain symptoms:* increased morning stiffness, night pain and synovial fluid effusion                                                                                                                                                                                                                                            Not specified                                                                                                                                                                                                                                                                                                                               Not specified                                                       Not specified              Not specified                                                                       None

  Marty 2009[@R20]                        'Flare'                              No measurement tool: morning stiffness\>20 min, nocturnal awakening, limping, knee swelling, increased warmth, effusion                                                                                                                                                                                                         Not specified                                                                                                                                                                                                                                                                                                                               Not specified                                                       48 hours                   Not specified                                                                       Regression analysis of cross-sectional data to validate proposed flare criteria

  Murphy 2015[@R69]                       'Flare'                              Investigator definition: inadequate pain relief for an episode of intense pain that is usually brought on by too much activityParticipant definitions: described in terms of pain quality, timing (onset and duration), antecedents and consequences*Pain magnitude:* increase in pain or 'intense' or 'severe' level of pain   *Pain:* ≥40 of 100 mm or ≥4 of 10 on NRS                                                                                                                                                                                                                                                                                                    Patients described: 'Quick' or 'sudden'                             Patients: 10 s to 15 min   Patients: rest or take additional medication                                        For investigator definition: Battisti 2004, Pareek 2010[@R28] Plus researchers own experience

  Parry 2017[@R85]                        'Flare'                              *Pain:* recalled worst pain intensity in previous 6 months 0--10 NRS; ≥5                                                                                                                                                                                                                                                        *Pain:* recalled worse pain to be ≥2 points higher than recalled average pain (0--10 NRS) in previous 6 months                                                                                                                                                                                                                              Not specified                                                       Not specified              Not specified                                                                       Based on previous studies defining knee flares in OA and flares in diseases such as back pain and COPD

  Ricci 2005[@R54]                        'Flare-up'                           *Pain:* self-reported flare severity rating 0--10 NRS; increase≥2 point over usual pain severity                                                                                                                                                                                                                                Not specified                                                                                                                                                                                                                                                                                                                               Not specified                                                       Not specified              Not specified                                                                       Based on statistical analysis and clinical judgement

  Wise 2010[@R70]                         'Flare'                              Not specified                                                                                                                                                                                                                                                                                                                   *Pain:* WOMAC Pain subscale (0--10); score in highest 30% of all WOMAC scores                                                                                                                                                                                                                                                               Not specified                                                       Not specified              Not specified                                                                       None

  Zhang 2009[@R71]                        'Exacerbation or flare'              Not specified                                                                                                                                                                                                                                                                                                                   Pain: WOMAC pain subscale 0--10 (total score of 50 normalised to a 0--10 scale); score of ≥5, a score corresponding to highest 33% of all WOMAC scores                                                                                                                                                                                      Not specified                                                       Not specified              Not specified                                                                       None

  Zhang 2011[@R72] (abstract)             'Exacerbation'                       *Pain:* WOMAC Pain score VAS (0--500); increase≥100 units                                                                                                                                                                                                                                                                       Not specified                                                                                                                                                                                                                                                                                                                               Not specified                                                       Not specified              Not specified                                                                       None

  Zobel 2016[@R92]                        Exacerbation                         *Pain:* 0--10 NRS; increase≥2                                                                                                                                                                                                                                                                                                   Disabling pain                                                                                                                                                                                                                                                                                                                              Not specified                                                       8 hours                    Not specified                                                                       None
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

COPD, chronic obstructive pulmonary disease; KOFUS, Knee Osteoarthritis Flare-up Score; LK, Likert scale; NSAID, non-steroidal anti-inflammatory drug; NRS, Numerical Rating scale; VAS, Visual Analogue Scale; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.

One study used the term 'flare-up',[@R52] two studies referred simply to 'worsening of symptoms'[@R31] and three studies used no specific label.[@R34]

### Coverage of key components {#s3d2}

*Onset/worsening of symptoms and signs beyond normal-day-to-day variability*: forty-four studies included onset or worsening of signs and symptoms as part of their definition.[@R24] All studies included increased pain intensity in their definition. A further two[@R52] specified further signs and symptoms. These included swelling, inflammation, erythema, morning stiffness and nocturnal pain. No studies quantified day-to-day variability.

Twenty-six measurement tools were used to define onset/worsening of symptoms and signs. The most commonly used tools were the Western Ontario and McMaster Universities Arthritis index (WOMAC) Q1 (pain on walking on flat surface) 100 mm Visual Analogue Scale (VAS) (n=9)[@R29] and the Investigator Assessment of Disease Status (n=11)[@R28] ([table 3](#T3){ref-type="table"}). Thirty-four studies used only single-item measurement tools,[@R27] five used multiitem[@R31] and five used both single-item and multiitem tools.[@R24]

###### 

Summary of number and type of single-item and multiitem measurement tools used

  ------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Single-item scales:**         

  Pain on activity:               WOMAC Q1 3.0 VAS 'pain on walking on a flat surface' (0--100 mm) (n=11)\
                                  Pain on walking VAS (0--100 mm) (n=5)\
                                  Pain on movement VAS (0--100 mm); ambulatory pain (5-point Likert); pain with physical activity VAS 11-point scale (n=2)

  Pain (not further specified):   Pain VAS (0--100 mm) (n=15)\
                                  Patients assessment of pain score (0--10); pain scale (0--3); Pain NRS (0--10) (n=11)

  Standing knee pain              Item 5 WOMAC pain scale (n=1)

  Global rating\                  Investigator Assessment of Disease Status (n=11)\
  (physician/investigator)        Physicians Global Assessment of Arthritis (n=6)\
                                  Physician Global Assessment of OA (n=2)\
                                  Physician Global Assessment of Disease Status (n=2); Investigator Assessed Pain Grade; (Physician) Overall Disease Activity (0--100); Physicians Pain Assessment (4-point LK) (n=3)

  Global rating (patient)         Patients Global Assessment of Arthritis (n=7)\
                                  Patient Global Assessment of OA (n=3)\
                                  Patient Global Assessment of Disease Status (n=4)

  **Multiple-item scales:**       

                                  Lequesne OA Severity Index (n=5)\
                                  WOMAC LK3.1 (0--20) (n=3)\
                                  WOMAC LK Pain subscale (0--25); WOMAC OA Index Questionnaire (n=1); WOMAC knee pain score (0--500) \[n=7\]; KOFUS (0--14) (n=1)
  ------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

KOFUS, Knee Osteoarthritis Flare-up Score; LK, Likert scale; N, number of included studies; OA, osteoarthritis; VAS, Visual Analogue Scale; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.

In addition, the format of global ratings appears to be variable as is use and reporting of the WOMAC.[@R93] However, despite the exact format of reporting being inconsistent, in general, studies used single items in four areas---pain on activity, pain (not necessarily on activity), physician/investigator global rating and patient global rating.

*Temporal characteristics*: none of the included drug withdrawal design studies reported a specific time for defining the speed of onset of symptoms. However, they did describe withdrawal or 'washout' periods, whereby after withdrawal of usual medication, participants were given a certain time frame in which to experience 'flare' symptoms in order that they were entered into the study. In total 30 of the studies specified a withdrawal period.[@R27]

Four studies specified a time period for minimum duration of symptoms, which ranged from 24 hours to 5 days.[@R52]

*Change in medication or healthcare usage*: only one study used increase in medication as part of their definition; 'pain requiring supplemental analgesic medication and/or an increase in non-steroidal anti-inflammatory drug dose'.[@R57]

*Additional domains:* thirty-six studies included a minimum threshold, which was usually a minimum level of pain that was required before the participant was considered to have a flare.[@R24] There was general concordance with the minimum thresholds that different measurement tools used with a few exceptions. A threshold of 40 mm on a 0--100 mm scale was used in 8 of 10 studies using the WOMAC VAS 3.0 Q1 'pain on walking on a flat surface'[@R29] and 4 of 14 studies using the Patient Global Assessment of Disease Status.[@R29] In studies using various forms of Investigator/Physician Global Assessment, the majority adopted a minimum threshold for a flare of 'fair, poor or very poor'.[@R29] The minimum threshold on the Lequesne index (0--10) was either 5[@R53] or 7.[@R46]

Flare definitions in non-withdrawal flare/discontinuation studies {#s3e}
-----------------------------------------------------------------

### Terminology used {#s3e1}

'Flare' was the term most common used in non-withdrawal design studies[@R20] (n=11) ([table 2](#T2){ref-type="table"}). One study used the term 'flare-up',[@R54] eight used 'exacerbation'[@R44] (five publications were from the same team) and one referred to both 'exacerbation' and 'flare'.[@R71] None referred to 'worsening of symptoms' or did not use any specific label.

### Coverage of key components {#s3e2}

*Onset/worsening of symptoms and signs beyond normal day-to-day variability:* 16 of 22 studies used onset or worsening of symptoms in their definition.[@R25] Two studies did not use pain intensity as part of its definition.[@R20] Three studies included symptoms other than pain in their definition.[@R20] These included nocturnal awakenings, effusion, morning stiffness, night pain, limping and warmth.

The study by Murphy *et al*[@R69] included an investigator definition of flare and sought to describe patient experience of flares through face-to-face individual interviews. Both investigator and patient definitions included onset/worsening of symptoms and signs; however, there was no differentiation from day-to-day variability.

Seven studies used a measurement tool to define onset of signs and symptoms ([table 3](#T3){ref-type="table"}). These included the Pain NRS (0--10),[@R25] WOMAC knee pain score VAS (0--500),[@R72] pain walking on a flat surface (WOMAC),[@R86] Global Assessment of Disease Status (physician) (5-point Likert scale)[@R86] and knee pain VAS not further specified (0--100).[@R44]

*Temporal characteristics*: only one study set a definition for speed of onset, describing this only as 'sudden' with no further specification.[@R66] Patients in the study by Murphy *et al* used the terms 'quick' and 'sudden' to describe flare onset.[@R69] Three studies specified a minimum duration of symptoms ranging from 8 to 48 hours.[@R20] In the study by Murphy *et al*, patients described duration between 10 s and 15 min.[@R69]

*Change in medication/healthcare usage*: no studies used change is medication or healthcare usage as part of their definition. However, in the study by Murphy *et al*, patients reported either taking rest or using additional medication.[@R69]

*Additional domains:* two studies defined distribution-based minimum thresholds for flare as the highest 30%^72^ or highest 33%^73^ of WOMAC Pain subscale scores among participants in the Longitudinal Examination of Arthritis Pain cohort (total score out of 50 was normalised to a 0--10 scale).

Discussion {#s4}
==========

Flares in OA are recognised in existing clinical guidance[@R94] and reviews,[@R95] but typically merit little more than a passing mention. Our analysis of the definitions has resulted in the findings of common core domains, which will be useful for developing an agreed consensus definition for OA flare. From a clinical perspective, a unified definition of a flare could enable clinicians to provide prompt, rationalised and focused treatment. This could also have implications for delivery of self-management strategies involving patients and how episodic management is advocated by clinical guidelines. Our review was motivated by an interest in seeking greater clarity on how these phenomena might be defined by undertaking a broad search strategy, noting that similar efforts have been pursued in other chronic diseases. While we found no current single, agreed definition of OA flare, our review of 69 published studies suggests a number of common domains, which may capture cardinal features. These were: onset/worsening of symptoms and signs, attainment of a minimum symptom threshold during flare, speed of onset/worsening and duration of elevated symptoms/signs. However, we found considerable variation in how these domains have been operationalised for measurement suggesting the need for further conceptual clarification and consensus.

Each potential cardinal feature of OA flare presents different challenges for achieving consensus. The goal of an agreed composite definition is to facilitate both reproducible and comparable research, while enabling more consistent recognition and identification of these phenomena in routine practice. The heterogeneity of OA should also be considered in any definition of a flare-up. Most studies included in our review required an increase in pain over 'usual' or 'baseline' intensity. Although this was measured using a wide range of measurement instruments, several studies selected an increase of 2 or more points on a 0--10 scale providing a possible starting point for consensus. Yet this possible 'signal' is arguably difficult to interpret without also considering the amount of background 'noise', that is, within-person diurnal[@R97] and day-to-day variability,[@R98] and the absolute level ('minimum threshold') of pain during a flare. There was general concurrence with the minimum threshold that was adopted, for example, 40 mm on a 0--100 mm scale and this may indicate the potential level of minimally important clinical difference. In the study by Marty *et al*, an increase in pain was not independently associated with flare-up after adjusting for other potential features.[@R20] However, the studies by Marty *et al*[@R20] and Scott-Lennox *et al*[@R56] were the only ones that had attempted to derive and/or validate a prediction model for OA flares. Interestingly, their approaches have not been widely adopted which suggests the complexity of reaching a widely accepted model. Further research on detecting flares over within-person 'normal' variability by collecting frequent repeated measures of pain intensity may be valuable but this approach would not be feasible when identifying flares presenting at the point of care in routine clinical practice. Instead, this may have to rely on the judgement of the patient and/or clinician, the approach used, for example, in defining exacerbations in COPD.[@R1] A similar consideration surrounds the speed of onset, which was not well defined by studies in our review. Drug withdrawal design studies specified washout periods between 2 and 15 days, but this is unlikely to be synonymous with speed of onset. The remaining studies used terms such as 'sudden' and 'quick'. In COPD, for instance, a judgement around 'acute onset' or 'sudden onset' appears to be acceptable for clinical recommendations, but we would add that the speed of onset of OA flares ought to be considered also in relation to underlying biologically plausible mechanisms. Indeed, presumed aetiology has been argued as a useful feature in defining acute exacerbations in COPD.[@R99] Minimum duration ranged from 8 hours to 5 days in our review; however, this was not widely reported. COPD definitions refer to a 'sustained worsening' of symptoms,[@R2] but does not appear to be a feature in other chronic diseases. A minimum duration in OA may help distinguish flares from day-to-day variability. Increase in medication was not found to be a key component in this review despite it being a feature in other chronic diseases such as AS,[@R5] SLE,[@R4] inflammatory bowel disease and[@R101] COPD.[@R1] Interference with function did not emerge strongly from our review as a cardinal feature of OA flare. In other chronic musculoskeletal conditions, such as back pain, interference with function was not shown to be significantly associated with having a flare-up[@R102] and this domain does not feature in the definitions of exacerbations or flares in diseases such as COPD,[@R1] asthma,[@R3] AS[@R5] or SLE.[@R4]

Our review has several strengths and some weaknesses that deserve attention. We adopted a broad search strategy, covering a wide range of databases, and featuring bibliography checks, contact with authors, inclusion of conference abstracts, no language restrictions and a minimal threshold (any description or definition of flare) for inclusion. Five studies that were included in a similar review by Cross *et al*[@R103] were not included in this study; four did not contain a clear definition of flare-up, including one which gave a definition of knee OA progression and the final paper by Sands *et al*[@R104] was not in our search but the original study was.[@R58] We did not, however, search the grey literature and we did not include some potential synonyms as search terms ('attack', 'episode', 'fluctuations'), although these terms appeared often to relate to comorbidities and other phenomena (eg, episodes of care) and would therefore have been a less efficient search strategy than relying on snowball references. Data extraction was performed by only a single reviewer. Nevertheless, we argue that our review provides a reasonably comprehensive summary of how 'flares' in OA have been described and defined in the medical literature. In comparison with the study by Cross *et al*,[@R103] our search strategy appeared comprehensive yet efficient---returning 69 included articles compared with 23. We feel that our review expands on the findings of the review by Cross *et al* and adds strength to this important area. The majority of studies describe experimental 'flare design' trials in which flares are induced by drug withdrawal prior to enrolment and randomisation. While intentional or unintentional reduction in usual analgesia may indeed be one trigger for flare, experimentally induced flares should not be assumed to represent 'naturally occurring' flares. Flare design trials, for example, are unlikely to capture change in management or healthcare usage that may be a common consequence of OA flares---something that is included in flare definitions in other conditions such as AS,[@R5] SLE,[@R4] inflammatory bowel disease[@R101] and COPD.[@R1]

A systematic review such as this cannot hope to resolve the need for a common conception and definition of flares in OA. Definitions for exacerbations of disease states are generally reached through a long process of consensus exercises involving key stakeholders, experts and patients in addition to appraisal of relevant literature from studies using multiple methods.[@R6] However, we believe that a consensus definition that is reliable, valid and feasible and widely acceptable both clinically and for research purposes should now be sought. The cardinal features described in this review; onset/worsening of symptoms and signs, attainment of a minimum symptom threshold during flare, speed of onset/worsening and duration of elevated symptoms/signs could help start this discussion. Furthermore, observational studies with repeated measures could give an important insight into the nature of these phenomena.

Conclusion {#s5}
==========

A broad range of ad hoc definitions currently exist in the medical literature. The majority are from drug withdrawal or flare-induced trials rather than 'naturally' occurring flares. The cardinal feature is pain intensity with minimum symptom threshold being another important feature. This review has identified the need to gain consensus on a common definition that can be used for research and clinical application.
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